石藥(01093.HK)治療骨鉅細胞瘤新藥關鍵臨牀試驗達預設終點
石藥集團(01093.HK)公佈,附屬上海津曼特生物科技的1類新藥JMT103用於治療不可切除或手術困難的骨鉅細胞瘤關鍵臨牀試驗達到預設終點。基於研究結果,集團已向國家藥監局遞交上市前溝通交流的申請。
JMT103爲創新型全人源RANKL單克隆抗體。集團在中國開展了兩項臨牀研究(JMT103CN03 和 JMT103CN03-1)作爲JMT103治療不可切除或手術困難骨鉅細胞瘤的關鍵臨牀試驗,用於支持該產品上市申報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.